Trial Profile

Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sulindac (Primary)
Indications Malignant melanoma
Focus Pharmacokinetics

Most Recent Events

26 Dec 2017 Biomarkers information updated
24 Jul 2012 Status changed from active, no longer recruiting to completed, based on final results published in Cancer.
14 Jun 2012 Actual patient number changed from 51 to 50 as reported by ClincialTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com